Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$8.69 USD

8.69
111,109

-0.04 (-0.46%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $8.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM

Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM

    Sanghamitra Saha headshot

    Looking for Earnings Beat? Play These Top 5 Stocks

    These top-ranked stocks may surpass bottom-line estimates in their next release.

      Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

      Style Box ETF report for DWAS

        Inogen (INGN) Up 14.7% Since Last Earnings Report: Can It Continue?

        Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Inogen (INGN) Soars to 52-Week High, Time to Cash Out?

          Inogen (INGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

            Here's Why You Should Buy Inogen (INGN) Stock Right Now

            Inogen (INGN) gains from strong Q2 results and bright global prospects.

              Can Inogen (INGN) Stock Continue to Grow Earnings?

              Inogen (INGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

                Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails

                Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.

                  Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now (Revised)

                  Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.

                    Align Technology International Growth Solid, Rivalry Rife

                    Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.

                      Why You Should Add Chemed (CHE) Stock to Your Portfolio Now

                      Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.

                        DaVita Healthcare Partners' New Facility Now in Los Angeles

                        DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.

                          Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now

                          Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.

                            Masimo (MASI) Scales a 52-Week High: What's Driving It?

                            Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.

                              Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?

                              Medtronic (MDT) poised to gain on continued growth in RTG business in Q1.

                                Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?

                                Medtronic (MDT) poised to gain on strength in Diabetes business in Q1 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.

                                  Haemonetics Strong on Plasma Unit Amid Blood Center Weakness

                                  Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.

                                    Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure

                                    Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.

                                      Hologic Launches Fluent Fluid Management System, Widens Suite

                                      Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.

                                        CVS Health's PBM Selling Season Strong, Aetna Deal on Track

                                        A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.

                                          Amedisys (AMED) Grows on Robust Home Health, Personal Care

                                          Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.

                                            Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?

                                            Is (INGN) Outperforming Other Medical Stocks This Year?

                                              Here's Why You Should Invest in Align Technology (ALGN) Now

                                              We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.

                                                AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology

                                                AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.

                                                  Wright Medical Strong Overseas, Back Order Issues Persist

                                                  Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.